title: New sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem-cell transplantation in very high-risk acute myeloid leukemia.
authors.affiliation: Department of Hematology, CHU Nice, France. cluzeau.thomas@gmail.com
authors.forename: Thomas
authors.initials: T
authors.lastname: Cluzeau
authors.forename: Muriel
authors.initials: M
authors.lastname: De Matteis
authors.forename: Nicolas
authors.initials: N
authors.lastname: Mounier
authors.forename: Lionel
authors.initials: L
authors.lastname: Mannone
authors.forename: Nicole
authors.initials: N
authors.lastname: Gratecos
authors.forename: Michel
authors.initials: M
authors.lastname: Ticchioni
authors.forename: Antoine
authors.initials: A
authors.lastname: Thyss
authors.forename: Sophie
authors.initials: S
authors.lastname: Raynaud
authors.forename: Jill-Patrice
authors.initials: JP
authors.lastname: Cassuto
authors.forename: Anne
authors.initials: A
authors.lastname: Sirvent
mesh_terms: D000328:Adult; D000961:Antilymphocyte Serum / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D018572:Disease-Free Survival; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006086:Graft vs Host Disease / Q000401:mortality / Q000628:therapy; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000401:mortality* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D033581:Stem Cell Transplantation; D015996:Survival Rate; D013852:Thiotepa / Q000008:administration & dosage; D013997:Time Factors; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D000961:Antilymphocyte Serum; D005047:Etoposide; D013852:Thiotepa; D014740:Vidarabine; C024352:fludarabine